Bicycle Therapeutics PLC
NASDAQ:BCYC

  • LAST PRICE
    23.3700
  • TODAY'S CHANGE (%)
    0.6400 (2.8157%)
  • Bid / Lots
    23.3600/ 2
  • Ask / Lots
    23.3900/ 4
  • Open / Previous Close
    22.8900 / 22.7300
  • Day Range
    22.7400
    24.1800
  • 52 Week Range
    12.5400
    28.9100
  • Volume
    107,367

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
BCYC
Bicycle Therapeutics PLC
863.0M
-4.6x
---
RLAY
Relay Therapeutics Inc
835.6M
-2.4x
---
IMNM
Immunome Inc
819.6M
-4.2x
---
TNGX
Tango Therapeutics Inc
794.0M
-7.3x
---
SSII
SS Innovations International Inc
851.9M
-38.6x
---
CNTA
Centessa Pharmaceuticals PLC
894.7M
-5.9x
---
As of 2024-04-29

Company Information

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a class of medicines, which it refers to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are therapeutic modality combining the pharmacology usually associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Its product candidates BT5528, BT8009 and BT1718, are each a Bicycle Toxin Conjugate (BTC). BT5528 is a second-generation BTC designed to target Ephrin type A receptor 2 (EphA2). BT8009 is a second-generation BTC designed to target Nectin-4, a validated tumor antigen. BT1718 is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase (MT1 MMP). Its product candidates BT7480 and BT7455, are each a Bicycle tumor-targeted immune cell agonist (TICA). The Company is also focused on additional therapeutic areas other than its wholly owned oncology portfolio.

Contact Information

Headquarters
Blocks A & B, Portway Building, Granta PCAMBRIDGE, United Kingdom CB21 6GS
Phone
122-326-1503
Fax
---

Executives

Non-Executive Chairman of the Board
Pierre Legault
Chief Executive Officer, Executive Director
Kevin Lee
Chief Financial Officer, Principal Financial Officer
Alethia Young
Chief Operating Officer
Alistair Milnes
Chief Technology Officer
Michael Skynner

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$863.0M
Revenue (TTM)
$27.0M
Shares Outstanding
38.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.91
EPS
$-5.13
Book Value
$8.74
P/E Ratio
-4.6x
Price/Sales (TTM)
32.0
Price/Cash Flow (TTM)
---
Operating Margin
-704.13%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.